Overall, our findings indicate that these new FOXM1 targeting compounds may have therapeutic potential in treating TNBC with the aim of reducing tumor progression and metastatic outgrowth, and hopefully providing clinical benefit ultimately to patients with this aggressive type of breast cancer. The gene discussed is FOXM1; the disease is breast cancer.